Taihe Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TIHE research report →
About the company
Currently, Taihe Group, Inc. is not engaged in substantial operational activities. Historically, the company functioned as a commercial laboratory, providing specialized predictive tests for chemosensitivity and immunotherapy on biopsy samples, alongside a variety of other laboratory services and products within the field of oncology.
- CEO
- Yan Ping Sheng
- IPO
- 1998
- Employees
- 3
- HQ
- Scottsdale, AZ, US
Price Chart
- Market Cap
- $71.85M
- P/E
- -1428.57
- P/S
- 0.00
- P/B
- -1428.57
- EV/EBITDA
- -1635.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.81%
- ROIC
- 2107.72%
- Revenue
- $0 · 0.00%
- Net Income
- $-43,967 · -50.47%
- EPS
- $-0.00 · 99.99%
- Op Income
- $-43,967
- FCF YoY
- -43.33%
- 52W High
- $3.30
- 52W Low
- $1.00
- 50D MA
- $1.00
- 200D MA
- $2.51
- Beta
- 1.23
- Avg Volume
- 0
Get TickerSpark's AI analysis on TIHE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TIHE coverage
Recent articles, reports, and earnings notes.
No research on TIHE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TIHE report →Similar companies
Peers in the same neighborhood.